Alexander B. Radaoui
A5010551333- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Neuroblastoma Research and Treatments
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Virus-based gene therapy research
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- RNA Interference and Gene Delivery
- Enzyme Production and Characterization
Children's Hospital of Philadelphia
2019-2024
Abstract Purpose: Ewing sarcoma is the second most common bone in children, with 1 case per 1.5 million United States. Although survival rate of patients diagnosed localized disease approximately 70%, this decreases to 30% for metastatic and only 10% treatment-refractory disease, which have not changed decades. Therefore, new therapeutic strategies are urgently needed refractory sarcoma. Experimental Design: This study analyzed 19 unique patient- or cell line–derived xenografts (from 14...
Summary Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor specimens along with normal tissues to identify biologically relevant proteins that can serve as immunotherapeutic neuroblastoma, often-fatal childhood cancer the developing nervous system. We apply this approach human-derived lines (N=9)...
<div>AbstractPurpose:<p>Ewing sarcoma is the second most common bone in children, with 1 case per 1.5 million United States. Although survival rate of patients diagnosed localized disease approximately 70%, this decreases to 30% for metastatic and only 10% treatment-refractory disease, which have not changed decades. Therefore, new therapeutic strategies are urgently needed refractory Ewing sarcoma.</p>Experimental Design:<p>This study analyzed 19 unique patient- or...
<p>Scoring schema to prioritize candidate immunotherapy targets.</p>
<p>ENPP1 immunofluorescence.</p>
<p>Expression of ATP11C, SLCO5A1, and STEAP2 in publicly available datasets.</p>
<p>Domain structure of ENPP1 and CDH11.</p>
<p>Statistical analysis (DEqMS) of proteins, EwS vs SuperMix</p>
<p>CDH11 expression in three publicly available datasets.</p>
<p>ENPP1 immunofluorescence.</p>
<p>Characteristics of proteins in the scoring schema.</p>
<p>Characteristics of proteins in the scoring schema.</p>
<p>Scoring schema to prioritize candidate immunotherapy targets.</p>
<p>Expression of known EwS surface proteins in cell line models and publicly available data.</p>
<p>Sample clustering of surface proteome data.</p>
<p>Sample clustering of surface proteome data.</p>
<p>Peptide coverage of all proteins and surface in the global surfaceome approaches.</p>
<p>Correlation between surfaceome and global proteome datasets.</p>
<p>CDH11 is a surface protein in EwS</p>
<p>Domain structure of ENPP1 and CDH11.</p>
<p>Consensus clustering of proteomics data.</p>